Document is current
Any future updates will be listed below
-
Authors
Okuda, Yusuke https://orcid.org/0000-0003-3707-695X
Mikami, Naoaki
Hamada, Riku
Hataya, Hiroshi
Tanaka, Kazuki
Terano, Chikako
Fujita, Naoya
Miura, Kenichiro
Ishizuka, Kiyonobu
Shirai, Yoko
Kamei, Koichi
Ogura, Masao
Okamoto, Takayuki
Suzuki, Ryota
Shinozuka, Shunsuke
Shima, Yuko
Oka, Masafumi
Shimabukuro, Wataru
Tsukaguchi, Hiroyasu
Inagaki, Tetsuji
Nishiyama, Kei
Hashimoto, Taeko
Ito, Naoko
Yamamura, Tomohiko
Horinouchi, Tomoko
Ishikura, Kenji
Nakanishi, Koichi
Nozu, Kandai
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare
Kyowa Kirin
- License Information
-
More Information
Article History
Received: 15 April 2025
Accepted: 22 August 2025
First Online: 19 September 2025
Declarations
:
: The Japanese Society of Paediatric Nephrology led this study. KNo is a member of advisory groups for Kyowa Kirin Co. Ltd., Toa Eiyo LTD., Zenyaku Kogyo Co. Ltd., and Taisho Pharmaceutical Co. Ltd. KNo has a patent for developing exon-skipping therapy for Alport syndrome patients. KNo receives a grant from Zenyaku Kogyo and Torii Co. Ltd. KK has received research funding from the Public Foundation of Vaccination Research Center and the Taiju Life Social Welfare Foundation; donations from Chugai Pharmaceutical, Teijin Pharma, Kyowa Kirin, Taiho Pharmaceutical, Shionogi, Daiichi Sankyo, and Mitsubishi Tanabe Pharma; lecture fees from Terumo. KNa receives consulting fees from Kyowa Kirin Co. Ltd., AstraZeneca, Kaken Pharmaceutical Co., Ltd., Ono Pharmaceutical Co. Ltd., Renalys Pharma, Inc.; research fundings from Sanofi K.K. JCR Pharmaceuticals Co. Ltd., Daiichi Sankyo Company, LTD., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Asahi Kasei Corporation., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., MSD K.K., Shionogi Co. Ltd., CSL Behring; honoraria from Novartis Pharma K.K., Sanofi K.K., JCR Pharmaceuticals Co. Ltd., Taisho Toyama Pharmaceutical Co., AstraZeneca, Daiichi Sankyo Company, LTD., Teijin Pharma LTD., Chugai Pharmaceutical Co. Ltd., Miyarisan Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Astellas Pharma Inc., Asahi Kasei Corporation., Ono Pharmaceutical Co. Ltd.
: This study protocol was approved by the Institutional Review Board of Kobe University Graduate School of Medicine (B210096); the study adhered to the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects, established by the Ministry of Health, Labour, and Welfare, Japan. In accordance with the Ethical Guidelines, the requirement for informed consent was waived in most instances; written informed consent was obtained when necessary.
